The preventing recurrent vascular events and neurological worsening through intensive organized case-management (PREVENTION) trial protocol [clinicaltrials.gov identifier: NCT00931788].
BACKGROUND
Survivors of transient ischemic attack (TIA) or stroke are at high risk for recurrent vascular events and aggressive treatment of vascular risk factors can reduce this risk. However, vascular risk factors, especially hypertension and high cholesterol, are not managed optimally even in those patients seen in specialized clinics. This gap between the evidence for secondary prevention of stroke and the clinical reality leads to suboptimal patient outcomes. In this study, we will be testing a pharmacist case manager for delivery of stroke prevention services. We hypothesize this new structure will improve processes of care which in turn should lead to improved outcomes.


METHODS
We will conduct a prospective, randomized, controlled open-label with blinded ascertainment of outcomes (PROBE) trial. Treatment allocation will be concealed from the study personnel, and all outcomes will be collected in an independent and blinded manner by observers who have not been involved in the patient's clinical care or trial participation and who are masked to baseline measurements. Patients will be randomized to control or a pharmacist case manager treating vascular risk factors to guideline-recommended target levels. Eligible patients will include all adult patients seen at stroke prevention clinics in Edmonton, Alberta after an ischemic stroke or TIA who have uncontrolled hypertension (defined as systolic blood pressure (BP) > 140 mm Hg) or dyslipidemia (fasting LDL-cholesterol > 2.00 mmol/L) and who are not cognitively impaired or institutionalized. The primary outcome will be the proportion of subjects who attain 'optimal BP and lipid control'(defined as systolic BP < 140 mm Hg and fasting LDL cholesterol < 2.0 mmol/L) at six months compared to baseline; 12-month data will also be collected for analyses of sustainability of any effects. A variety of secondary outcomes related to vascular risk and health-related quality of life will also be collected.


CONCLUSIONS
Nearly one-quarter of those who survive a TIA or minor stroke suffer another vascular event within a year. If our intervention improves the provision of secondary prevention therapies in these patients, the clinical (and financial) implications will be enormous.
McAlister
Finlay A
FA
Division of General Internal Medicine, University of Alberta Hospital, 8440 112 Street, Edmonton, Canada. finlay.mcalister@ualberta.ca
Majumdar
Sumit R
SR
Padwal
Rajdeep S
RS
Fradette
Miriam
M
Thompson
Ann
A
Tsuyuki
Ross
R
Grover
Steven A
SA
Dean
Naeem
N
Shuaib
Ashfaq
A
JAMA. 2006 Dec 6;296(21):2563-71
17101639
N Engl J Med. 2008 Sep 18;359(12):1225-37
18753639
Stroke. 2002 Jun;33(6):1656-9
12053007
Stroke. 2007 Dec;38(12):3198-204
17962589
CMAJ. 2008 Feb 26;178(5):576-84
18299547
J Am Coll Cardiol. 2004 May 19;43(10):1738-42
15145092
Lancet. 2001 Sep 29;358(9287):1033-41
11589932
Stroke. 2007 Jun;38(6):1881-5
17431209
Can J Cardiol. 2008 Jun;24(6):465-75
18548143
Medicine (Baltimore). 2008 Nov;87(6):329-334
19011504
J Am Geriatr Soc. 1975 Oct;23(10):433-41
1159263
J Gen Intern Med. 2005 Dec;20(12):1091-6
16423096
Pharmacotherapy. 2000 Dec;20(12):1508-16
11130223
J Hypertens. 2006 Jun;24(6):1201-8
16685221
Stroke. 1999 Jan;30(1):16-20
9880382
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005182
16625627
Can J Cardiol. 2009 Oct;25(10):567-79
19812802
Lancet. 2007 Jan 27;369(9558):283-92
17258668
Lancet. 2007 Dec 1;370(9602):1829-39
18061058
Osteoporos Int. 2007 Mar;18(3):261-70
17086470
Ann Pharmacother. 2007 Nov;41(11):1770-81
17925496
J Manag Care Pharm. 2003 May-Jun;9(3):269-73
14613471
Lancet. 2007 Oct 20;370(9596):1432-42
17928046
Stroke. 2003 Nov;34(11):2741-8
14576382
Diabetes Care. 2003 Nov;26(11):3061-6
14578240
JAMA. 2002 Sep 18;288(11):1388-95
12234233
N Engl J Med. 2006 Aug 10;355(6):549-59
16899775
Lancet. 2005 Oct 8;366(9493):1267-78
16214597
Am Heart J. 2007 Jan;153(1):22.e1-8
17174632
Am J Hypertens. 1997 Oct;10(10 Pt 1):1097-102
9370379
Cochrane Database Syst Rev. 2000;(3):CD000336
10908471
Am J Med. 2007 Aug;120(8):734.e11-7
17679135
J Am Pharm Assoc (2003). 2008 Jan-Feb;48(1):23-31
18192127
Stroke. 1997 Dec;28(12):2557-62
9412649
Neurology. 2004 Jun 8;62(11):2015-20
15184607
Lancet. 2002 Dec 14;360(9349):1903-13
12493255
J Gen Intern Med. 2009 Jan;24(1):33-9
18937013
CMAJ. 2009 Dec 8;181(12):E267-74
19948811
Arch Intern Med. 2007 Nov 26;167(21):2296-303
18039987
Fam Pract. 2007 Apr;24(2):189-200
17272285
Ann Intern Med. 2005 Nov 1;143(9):659-72
16263889
Lancet. 2002 Nov 2;360(9343):1347-60
12423980
Stroke. 1988 May;19(5):604-7
3363593
CMAJ. 2004 Nov 9;171(10):1189-92
15534311
CMAJ. 2006 Apr 25;174(9):1267-71
16595786
J Hypertens. 2007 May;25(5):951-8
17414657
Can J Neurol Sci. 2005 Nov;32(4):496-500
16408581
CMAJ. 2008 May 20;178(11):1418-25
18490636
JAMA. 2006 Jul 26;296(4):427-40
16868301
Arch Intern Med. 2002 May 27;162(10):1149-55
12020186
Lancet. 2008 Sep 27;372(9644):1174-83
18757085
Eur Heart J. 2003 Nov;24(21):1920-7
14585250
Pharmacotherapy. 2000 Nov;20(11):1375-83
11079286
CMAJ. 2005 Aug 30;173(5):496-501
16129870
Arch Intern Med. 2008 Nov 24;168(21):2355-61
19029501
Neurology. 2005 Sep 27;65(6):835-42
16186519
Lancet. 2004 Sep 11-17;364(9438):937-52
15364185
Health Rep. 2010 Mar;21(1):37-46
20426225
CMAJ. 2009 Dec 8;181(12):897-904
19933787
Arch Intern Med. 2007 May 28;167(10):1019-25
17533204
Lancet. 2003 Nov 8;362(9395):1527-35
14615107